Condition: Extensive Stage-small Cell Lung Cancer · Sponsor: Daiichi Sankyo
This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.
This description comes directly from the study's public registry record.
(US) Daiichi Sankyo Contact for Clinical Trial Information · 9089926400 · CTRinfo_us@daiichisankyo.com
(Asia) Daiichi Sankyo Contact for Clinical Trial Information · +81-3-6225-1111 (M-F 9-5 JST · dsclinicaltrial@daiichisankyo.co.jp
Always discuss trial participation with your own doctor first.
| University of Alabama -Birmingham | Birmingham, Alabama, United States | Recruiting |
| Mayo Clinic Arizona | Phoenix, Arizona, United States | Recruiting |
| David Geffen School of Medicine | Los Angeles, California, United States | Not Yet Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Recruiting |
| Mayo Clinic-Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Advent Health Orlando | Orlando, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago, Illinois, United States | Recruiting |
| Henry Ford Hospital | Detroit, Michigan, United States | Active Not Recruiting |
| Regents of the University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Dartmouth-Hitchcock Medical Center | Lebanon, New Hampshire, United States | Recruiting |
+ 46 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06362252